News

SPRING 2006 (January - May 2006)
News relating to New Haven, Connecticut, New Ventures Originating from Yale Research, and the Yale Pipeline

Achillion Pharmaceuticals Inc., a New Haven, Conn.-based drug company focused on infectious diseases, has filed to raise $75 million via an IPO of common stock. It plans to trade on the Nasdaq under ticker symbol ACHN, with Cowen & Co. and CIBC World Markets serving as lead underwriters. The company has raised around $100 million in total VC funding since its 1998 inception, from firms like Atlas Venture, SV Life Sciences, Advent International, Bear Stearns Health Innoventures, SGC Partners, Gilead Sciences and Connecticut Innovations.

Alexion Pharmaceuticals Inc. (ALXN) Completes Patient Treatment in its Phase III Pivotal TRIUMPH Efficacy Trial of Eculizumab in PNH Patients. By Abram Katz. January 4, 2006. BioSpace.

Pharmaceutical Firm Attempts to Attack Bacteria through Ribosomes. By Abram Katz. December 4, 2005. New Haven Register.

Marinus Pharmaceuticals Raises $29.4 Million in Series A Financing. October 25, 2005. BioSpace.com.

Marinus Pharmaceuticals Inc., a Bradford, Conn.-based drug company focused on neurological and psychiatric disorders, has raised $28.14 million in Series A funding, according to a regulatory filing. Backers include Domain Associates and Sofinnova Venture Partners. The company has a Phase III clinical candidate to treat infantile spasms, and has in-licensed from Yale University a preclinical compound to treat bipolar disorder. October 20, 2005. Private Equity Week, Thomson Financial.

HistoRx, Inc. and Eli Lilly Enter into a Collaboration. October 13, 2005. HistoRx.

HistoRx and Eli Lilly Enter into a Collaboration. October 13, 2005. Mass High Tech.